Ver registro no DEDALUS
Exportar registro bibliográfico

Metrics


Metrics:

Autoantibodies and other serological markers in rheumatoid arthritis: predictors of disease activity? (2009)

  • Authors:
  • USP affiliated authors: CARVALHO, JOZELIO FREIRE DE - FM
  • USP Schools: FM
  • DOI: 10.1007/s10067-009-1223-y
  • Subjects: AUTOANTICORPOS; BIOMARCADORES; ARTRITE REUMATOIDE (IMUNOLOGIA)
  • Language: Inglês
  • Imprenta:
  • Source:
  • Acesso online ao documento

    Online accessDOI or search this record in
    Informações sobre o DOI: 10.1007/s10067-009-1223-y (Fonte: oaDOI API)
    • Este periódico é de assinatura
    • Este artigo NÃO é de acesso aberto
    • Cor do Acesso Aberto: closed
    Informações sobre o Citescore
  • Título: Clinical Rheumatology

    ISSN: 0770-3198

    Citescore - 2017: 2.04

    SJR - 2017: 0.93

    SNIP - 2017: 0.877


  • Exemplares físicos disponíveis nas Bibliotecas da USP
    BibliotecaCód. de barrasNúm. de chamada
    FM10700094913-SFM BCBIB
    How to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      MOTA, Licia Maria Henrique da; SANTOS NETO, Leopoldo Luiz dos; CARVALHO, Jozélio Freire de. Autoantibodies and other serological markers in rheumatoid arthritis: predictors of disease activity? Clinical Rheumatology, Brussels, v. 28, n. 10, p. 1127-1134, 2009. Disponível em: < http://www.springerlink.com.w10077.dotlib.com.br/content/k1q73377x2555012/fulltext.pdf > DOI: 10.1007/s10067-009-1223-y.
    • APA

      Mota, L. M. H. da, Santos Neto, L. L. dos, & Carvalho, J. F. de. (2009). Autoantibodies and other serological markers in rheumatoid arthritis: predictors of disease activity? Clinical Rheumatology, 28( 10), 1127-1134. doi:10.1007/s10067-009-1223-y
    • NLM

      Mota LMH da, Santos Neto LL dos, Carvalho JF de. Autoantibodies and other serological markers in rheumatoid arthritis: predictors of disease activity? [Internet]. Clinical Rheumatology. 2009 ; 28( 10): 1127-1134.Available from: http://www.springerlink.com.w10077.dotlib.com.br/content/k1q73377x2555012/fulltext.pdf
    • Vancouver

      Mota LMH da, Santos Neto LL dos, Carvalho JF de. Autoantibodies and other serological markers in rheumatoid arthritis: predictors of disease activity? [Internet]. Clinical Rheumatology. 2009 ; 28( 10): 1127-1134.Available from: http://www.springerlink.com.w10077.dotlib.com.br/content/k1q73377x2555012/fulltext.pdf

    Referências citadas na obra
    Cabral D, Katz JN, Weinblatt ME, Ting G, Avorn J, Solomon DH (2005) Development and assessment of indicators of rheumatoid arthritis severity: results of a Delphi panel. Arthritis Rheum 53:61–66
    Khanna D, Oh M, Furst DE et al (2007) Evaluation of the preliminary definitions of minimal disease activity and remission in an early seropositive rheumatoid arthritis cohort. Arthritis Rheum 15(57):440–447
    Pincus T (2008) Limitations of a quantitative swollen and tender joint count to assess and monitor patients with rheumatoid arthritis. Bull NYU Hosp Jt Dis 66:216–223
    Mallya RK, de Beer FC, Berry H, Hamilton ED, Mace BE, Pepys MB (1982) Correlation of clinical parameters of disease activity in rheumatoid arthritis with serum concentration of C-reactive protein and erythrocyte sedimentation rate. J Rheumatol 19:224–228
    Ringold S, Singer NG (2008) Measures of disease activity in rheumatoid arthritis: a clinician’s guide. Curr Rheum Rev 4:259–265
    Prevoo MLL, Van’T Hof MA, Kuper HH, Van Leeuwen MA, Van De Putte LBA, Van Riel PLCM (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48
    Smolen JS, Breedveld FC, Schiff MH et al (2003) A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 42:244–257
    Aletaha D, Nell VP, Stamm T et al (2005) Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 7:R796–R806
    Devlin J (1997) The acute phase and function in early rheumatoid arthritis. C-reactive protein levels correlate with functional outcome. J Rheumatol 24:9–13
    Keenan RT, Swearingen CJ, Yazici Y (2008) Erythrocyte sedimentation rate and C-reactive protein levels are poorly correlated with clinical measures of disease activity in rheumatoid arthritis, systemic lupus erythematosus and osteoarthritis patients. Clin Exp Rheumatol 26:814–819
    Renaudineau Y, Jamin C, Saraux A, Youinou P (2005) Rheumatoid factor on a daily basis. Autoimmunity 38:11–16
    Vittecoq O, Pouplin S, Krzanowska K et al (2003) Rheumatoid factor is the strongest predictor of radiological progression of rheumatoid arthritis in a three-year prospective study in community-recruited patients. Rheumatology (Oxford) 42:939–946
    Visser H (2005) Early diagnosis of rheumatoid arthritis. Best Pract & Res Clin Rheum 19:55–72
    Visser H, Gelinck LB, Kampfraath AH, Breedveld FC, Hazes JM (1996) Diagnostic and prognostic characteristics of the enzyme linked immunosorbent rheumatoid factor assays in rheumatoid arthritis. Ann Rheum Dis 55:157–161
    Wolfe F, Cathey MA, Roberts FK (1991) The latex test revised rheumatoid factor testing in 8287 rheumatic disease patients. Arthritis Rheum 34:951–960
    Swedler W, Wallman J, Froelich CJ, Teodorescu M (1997) Routine measurement of IgM, IgG, and IgA rheumatoid factors: high sensitivity, specificity, and predictive value for rheumatoid arthritis. J Rheumatol 24:1037–1044
    Lemm G, Ruschen S, Warnatz H (1988) An ELISA for IgA-IgG and IgM-RF measurement II. RF in several disease and control groups and under gold therapy in RA. Scand J Rheumatol Suppl 75:256–260
    Bobbio-Pallavicini F, Alpini C, Caporali R, Avalle S, Bugatti S, Montecucco C (2004) Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthritis Res Ther 6:R264–R272
    Bobbio-Pallavicini F, Caporali R, Alpini C et al (2007) High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis. Ann Rheum Dis 66:302–307
    Bos WH, Bartelds GM, Wolbink GJ et al (2008) Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis. J Rheumatol 35:1972–1977
    Ates A, Kinikli G, Turgay M, Akay G, Tokgöz G (2007) Effects of rheumatoid factor isotypes on disease activity and severity in patients with rheumatoid arthritis: a comparative study. Clin Rheumatol 26:538–545
    Vallbracht I, Rieber J, Oppermann M, Förger F, Siebert U, Helmke K (2004) Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Ann Rheum Dis 63:1079–1084
    Greiner A, Plischke H, Kellner H, Gruber R (2005) Association of anti-cyclic citrullinated peptide antibodies, anti-citrullin antibodies, and IgM and IgA rheumatoid factors with serological parameters of disease activity in rheumatoid arthritis. Ann N Y Acad Sci 1050:295–303
    Raza K, Breese M, Nightingale P et al (2005) Predictive value of antibodies to cyclic citrullinated peptides in patients with very early inflammatory arthritis. J Rheumatol 32:231–238
    Solbritt RD, Ben AWJ, Berglin E, Hallmans G et al (2003) Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 48:2741–2749
    Svärd A, Kastbom A, Reckner-Olsson A, Skogh T (2008) Presence and utility of IgA-class antibodies to cyclic citrullinated peptides in early rheumatoid arthritis: the Swedish TIRA project. Arthritis Res Ther 10:R75
    Serdaroglu M, Cakirbay H, Defer O, Cengiz S, Kul S (2008) The association of anti-CCP antibodies with disease activity in rheumatoid arthritis. Rheumatol Int 28:965–970
    Mathson L, Mullazei M, Wick MC et al (2008) Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis Rheum 58:36–45
    Ursum J, Nielen MMJ, van Schaardenburg D, van der Horst AR, van de Stadt RJ, Dijkmans BA (2008) Antibodies to mutated citrullinated vimentin and disease activity score in early arthritis: a cohort study. Arthritis Res Ther 10:R12
    Innala L, Kokkonen H, Ericsson C, Jidell E, Berglin E, Rantapää-Dahlqvist S (2008) Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides. J Rheumatol 5:1002–1008
    Ursum J, Nielen MMJ, Schaardenburg DV, van der Horst AR, van de Stadt RJ, Dijkmans BA (2008) Antibodies to mutated citrullinated vimentin and disease activity score in early arthritis: a cohort study. Arthritis Res Ther 10:1–6
    Cordonnier C, Meyer O, Palazzo E, De Bandt M, Elias A, Nicaise P et al (1996) Diagnostic value of anti-RA33 antibody, antikeratin antibody, antiperinuclear factor and antinuclear antibody in early rheumatoid arthritis: comparison with rheumatoid factor. Br J Rheumatol 35:620–624
    Vittecoq O, Incaurgarat B, Jouen-Beades F et al (2004) Autoantibodies recognizing citrullinated rat filaggrin in an ELISA using citrullinated and non-citrullinated recombinant proteins as antigens are highly diagnostic for rheumatoid arthritis. Clin Exp Rheumatol 135:173–180
    Nielen MM, van der Horst AR, van Schaardenburg D et al (2005) Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis. Ann Rheum Dis 64:1199–1204
    Graudal N, Svenson M, Tarp U, Garred P, Jurik A, Bendtzen K (2002) Autoantibodies against interleukin-1 alfa in rheumatoid arthritis: association with long-term radiographic outcome. Ann Rheum Dis 61:598–602
    Saulot V, Vittecoq O, Charlionet R et al (2002) Presence of autoantibodies to the glycolytic enzyme alpha-enolase in sera from patients with early rheumatoid arthritis. Arthritis Rheum 46:1196–1201
    Newkirk MM, Goldbach-Mansky R, Lee J et al (2003) Advanced glycation end-product (AGE)-damaged IgG and IgM autoantibodies to IgG-AGE in patients with early synovitis. Arthritis Res Ther 5:R82–90
    Garnero P, Delmas PD (2004) Noninvasive techniques for assessing skeletal changes in inflammatory arthritis: bone biomarkers. Curr Opin Rheumatol 16:428–434
    Mohammed F, Smookler D, Khokha R (2003) Metalloproteinases, inflammation, and rheumatoid arthritis. Ann Rheum Dis 62:43–47
    Jensen T, Klarlund M, Hansen M (2004) Connective tissue metabolism in patients with unclassified polyarthritis and early rheumatoid arthritis. Relationship to disease activity, bone mineral density and radiographic outcomes. J Rheumatol 31:1698–1708
    Posthumus MD, Limburg PC, Westra J, van Leeuwen MA, van Rijswijk MH (2000) Serum matrix metalloproteinase 3 in with early rheumatoid arthritis is correlated with disease activity and radiological progression. J Rheumatol 27:2761–2768
    Posthumus MD, Limburg PC, Westra J, van Leeuwen MA, van Rijswijk MH (2003) Serum matrix metalloproteinase 3 levels in comparison to C-reactive protein in periods of radiological damage in patients with early rheumatoid arthritis. Clin Exp Rheumatol 21:465–472
    Green MJ, Gough AKS, Devlin J, Smith J, Astin P, Taylor D (2003) Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. Rheumatology (Oxford) 42:83–88
    Majeed M, McQueen F, Yeoman S, McLean L (2004) Relationship between serum hyaluronic acid level and disease activity in early rheumatoid arthritis. Ann Rheum Dis 63:1166–1168
    Garnero P, Landewé R, Boers M et al (2002) Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study. Arthritis Rheum 46:2847–2856
    Landewé R, Geusens P, Boers M, van der Heijde D, Lems W, te Koppele J (2004) Markers for type II collagen breakdown predict the effect of disease modifying treatment on long-term radiographic progression in patients with rheumatoid arthritis. Arthritis Rheum 50:1390–1399
    Landewé RB, Geusens P, van der Heijde DM, Boers M, van der Linden SJ, Garnero P (2006) Arthritis instantaneously causes collagen type I and type II degradation in patients with early rheumatoid arthritis: a longitudinal analysis. Ann Rheum Dis 65:40–44
    Charni N, Juillet F, Garnero P (2005) Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 52:1081–1090
    Jansen LMA, van der Horst-Bruinsma IE, Lems WF (2004) Serological bone markers and joint damage in early polyarthritis. J Rheumatol 31:1491–1496
    Forslind K, Eberhardt K, Jonsson A, Saxne T (1992) Increased serum concentrations of cartilage oligomeric matrix protein. A prognostic marker in early rheumatoid arthritis. Br J Rheumatol 31:593–598
    Soderlin MK, Kastbom A, Kautiainen H, Leirisalo-Repo M, Strandberg G, Skogh T (2004) Antibodies against cyclic citrullinated peptide (CCP) and levels of cartilage oligomeric matrix protein (COMP) in very early arthritis: relation to diagnosis and disease activity. Scand J Rheumatol 33:185–188
    Crnkic M, Månsson B, Larsson L, Geborek P, Heinegård D, Saxne T (2003) Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept. Arthritis Res Ther 5:R181–R185
    György B, Tóthfalusi L, Nagy G et al (2008) Natural autoantibodies reactive with glycosaminoglycans in rheumatoid arthritis. Arthritis Res Ther 10:R110
    Morgante M, Di Munno O, Morgante D (1999) YKL 40: marker of disease activity in rheumatoid arthritis? Minerva Med 90:437–441
    Johansen JS, Stoltenberg M, Hansen M et al (1999) Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity. Rheumatology (Oxford) 38:618–626
    Matsumoto T, Tsurumoto T (2001) Serum YKL-40 levels in rheumatoid arthritis: correlations between clinical and laboratory parameters. Clin Exp Rheumatol 19:655–660
    Jäälinoja J, Nissilä M, Kauppi MJ et al (2008) Serum antibodies against intact human collagen IX are elevated at onset of rheumatoid arthritis but are not related to development of erosions. J Rheumatol 35:745–751
    Saevarsdottir S, Vikingsdottir T, Vikingsson A, Manfredsdottir V, Geirsson AJ, Hl V (2001) Low mannose binding lectin predicts poor prognosis in patients with early rheumatoid arthritis. A prospective study. J Rheum 28:728–734
    Grauldal N (2004) The natural history and prognosis of rheumatoid arthritis: association of radiographic outcome with process variables, joint motion and immune proteins. Scand J Rheumatol Suppl 118:1–38
    Kuuliala A, Eberhardt K, Takala A, Kautiainen H, Repo H, Leirisalo-Repo M (2002) Circulating soluble E-selectin in early rheumatoid arthritis: a prospective five year study. Ann Rheum Dis 61:242–246
    Corona-Sanchez EG, Gonzalez-Lopez L, Muñoz-Valle JF et al (2009) Circulating E-selectin and tumor necrosis factor-alpha in extraarticular involvement and joint disease activity in rheumatoid arthritis. Rheumatol Int 29:281–286
    Klimiuk PA, Sierakowski S, Domysławska I, Fiedorczyk M, Chwiećko J (2004) Reduction of soluble adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor levels in serum of rheumatoid arthritis patients following multiple intravenous infusions of infliximab. Arch Immunol Ther Exp (Warsz) 52:36–42
    Sugiyama E, Kuroda A, Hori F, Hori T, Taki H, Arai N (1995) Serum Interleukin-6 level is a sensitive parameter of disease activity in rheumatoid arthritis. J Clin Rheumatol 1:93–98
    Madhok R, Crilly A, Watson J, Capell HA (1993) Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis 52:232–234
    Targońska-Stepniak B, Majdan M, Dryglewska M (2008) Leptin serum levels in rheumatoid arthritis patients: relation to disease duration and activity. Rheumatol Int 28:585–591
    Seven A, Güzel S, Aslan M, Hamuryudan V (2009) Serum and synovial fluid leptin levels and markers of inflammation in rheumatoid arthritis. Rheumatol Int 29(7):743–747
    Gunaydin R, Kaya T, Atay A, Olmez N, Hur A, Koseoglu M (2006) Serum leptin levels in rheumatoid arthritis and relationship with disease activity. South Med J 99:1078–1083
    Hizmetli S, Kisa M, Gokalp N, Bakici MZ (2007) Are plasma and synovial fluid leptin levels correlated with disease activity in rheumatoid arthritis? Rheumatol Int 27:335–338